AI Biotechnology LLC - Nov 1, 2023 Form 3 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role: 10%+ Owner
Signature: /s/ Alejandro Moreno for AI Biotechnology LLC
Stock symbol: VYNE
Transactions as of: Nov 1, 2023
Transactions value $: $0
Form type: 3
Date filed: 11/13/2023, 08:30 AM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	VYNE	Common Stock						1.12M	Nov 1, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	VYNE	Warrant (right to buy)							Nov 1, 2023	Common Stock	7.79M	$0.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities reported are held directly by AI Biotechnology LLC ("AI Biotechnology") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AI Biotechnology. Each of the reporting persons (other than AI Biotechnology) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.
F2	Each pre-funded warrant is exercisable at any time after the date of issuance and the pre-funded warrants do not expire. The pre-funded warrants are not exercisable to the extent that the aggregate number of shares of Common Stock beneficially owned by AI Biotechnology immediately following such exercise would exceed 9.99%; provided, however, that AI Biotechnology may increase or decrease the beneficial ownership limitation by giving 60 days' notice to the Issuer, but not to exceed any percentage in excess of 19.99%.

Content

The securities reported are held directly by AI Biotechnology LLC ("AI Biotechnology") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AI Biotechnology. Each of the reporting persons (other than AI Biotechnology) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

Each pre-funded warrant is exercisable at any time after the date of issuance and the pre-funded warrants do not expire. The pre-funded warrants are not exercisable to the extent that the aggregate number of shares of Common Stock beneficially owned by AI Biotechnology immediately following such exercise would exceed 9.99%; provided, however, that AI Biotechnology may increase or decrease the beneficial ownership limitation by giving 60 days' notice to the Issuer, but not to exceed any percentage in excess of 19.99%.

Remarks:

Exhibit List: Ex.24 - Power of Attorney